**FOI Ref: 6535**

**Category(ies): Clinical - Drugs**

**Subject: Patient Treatment with Nivolumab 2**

**Date Received: 02/08/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| 1. In the last 3 months, how many patients have been initiated\* on the following agents for the treatment of melanoma?
* Nivolumab (monotherapy)
* Nivolumab AND Ipilimumab (combination)

\*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.   | Chemotherapy for the conditions in this question would be provided by Weston Park Hospital OncologyPlease redirect your request to Sheffield Teaching Hospitals NHS Foundation, who can be contacted via the email address foi@sth.nhs.uk |
| 1. In the last 3 months, how many patients have been initiated\* on the following agents for the treatment of Renal Cell Carcinoma?
* Nivolumab (monotherapy)
* Nivolumab + Ipilimumab
* Nivolumab + Cabozantinib
* Avelumab + Axitinib

\*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.  | Chemotherapy for the conditions in this question would be provided by Weston Park Hospital OncologyPlease redirect your request to Sheffield Teaching Hospitals NHS Foundation, who can be contacted via the email address foi@sth.nhs.uk |
| 1. In the past 3 months, how many patients have been initiated\* on the following agents for the treatment of upper gastrointestinal cancer (oesophagael cancer, gastric cancer and gastro-oesophageal junction cancer)?
* Nivolumab
* Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)

\*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.  | Chemotherapy for the conditions in this question would be provided by Weston Park Hospital OncologyPlease redirect your request to Sheffield Teaching Hospitals NHS Foundation, who can be contacted via the email address foi@sth.nhs.uk |
| 1. Does your trust participate in any clinical trials for the treatment of Melanoma? If so, please provide the name of each active trial, and the number of patients taking part.
 | No |
|  5. Does your trust participate in any clinical trials for the treatment of Renal Cell Carcinoma? If so, please provide the name of each active trial, and the number of patients taking part. | No |